Literature DB >> 14971549

Spinal muscular atrophy in the neonate.

Jennifer A Markowitz1, Mindy B Tinkle, Kenneth H Fischbeck.   

Abstract

Spinal muscular atrophy (SMA) type I is an autosomal recessive disorder characterized by loss of lower motor neurons in the spinal cord. This severe hereditary neurodegenerative disorder is an important cause of morbidity in the neonate and the leading hereditary cause of infant mortality. The characteristic degeneration of anterior horn cells in the spinal cord leads to progressive muscular weakness and atrophy of the skeletal muscles. In SMA type I, the most severe form of SMA, death usually ensues by 2 years of age from respiratory failure or infection. Accurate diagnosis is now available through genetic testing, and progress is being made toward the development of therapy based on understanding of the disease mechanism. The neonatal nurse plays a pivotal role in identifying and caring for these medically fragile infants and in providing support and education for parents and families.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971549     DOI: 10.1177/0884217503261125

Source DB:  PubMed          Journal:  J Obstet Gynecol Neonatal Nurs        ISSN: 0090-0311


  8 in total

1.  Deficiency of the zinc finger protein ZPR1 causes neurodegeneration.

Authors:  Beth Doran; Norberto Gherbesi; Gregory Hendricks; Richard A Flavell; Roger J Davis; Laxman Gangwani
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-28       Impact factor: 11.205

2.  A schematic approach to hypotonia in infancy.

Authors:  Joanna Leyenaar; Peter Camfield; Carol Camfield
Journal:  Paediatr Child Health       Date:  2005-09       Impact factor: 2.253

3.  Placental development in a mouse model of spinal muscular atrophy.

Authors:  Gerialisa Van Gronigen Caesar; Jeffrey M Dale; Erkan Y Osman; Michael L Garcia; Christian L Lorson; Laura C Schulz
Journal:  Biochem Biophys Res Commun       Date:  2015-12-31       Impact factor: 3.575

4.  Emerging treatment options for spinal muscular atrophy.

Authors:  Barrington G Burnett; Thomas O Crawford; Charlotte J Sumner
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

5.  Solution structure of the core SMN-Gemin2 complex.

Authors:  Kathryn L Sarachan; Kathleen G Valentine; Kushol Gupta; Veronica R Moorman; John M Gledhill; Matthew Bernens; Cecilia Tommos; A Joshua Wand; Gregory D Van Duyne
Journal:  Biochem J       Date:  2012-08-01       Impact factor: 3.857

6.  SMN1 dosage analysis in spinal muscular atrophy from India.

Authors:  Akanchha Kesari; Hanna Rennert; Debra G B Leonard; Balraj Mittal
Journal:  BMC Med Genet       Date:  2005-05-23       Impact factor: 2.103

7.  Anesthetic management of spinal muscle atrophy type II in a parturient.

Authors:  Laurent Bollag; Christopher Kent; Philippe Richebé; Ruth Landau
Journal:  Local Reg Anesth       Date:  2011-04-06

Review 8.  Zinc-finger proteins in health and disease.

Authors:  Matteo Cassandri; Artem Smirnov; Flavia Novelli; Consuelo Pitolli; Massimiliano Agostini; Michal Malewicz; Gerry Melino; Giuseppe Raschellà
Journal:  Cell Death Discov       Date:  2017-11-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.